If you could vote on Brexit now which option would you choose?
   

Merck's molnupiravir will be 'complementary, but not a competitor' to COVID-19 vaccines: analyst


What do Merck’s eye-opening data, recently released for its antiviral molnupiravir on high-risk COVID-19 patients, mean for manufacturers of vaccines? Analysts from the ODDO BHF financial services group see little impact in the short and intermediate term. Even though inoculation rates are low in most lesser developed countries, ODDO says it’s unlikely that countries will shift away from vaccination campaigns to focus primarily on treating high-risk patients with COVID. This is the case despite trial data showing molnupiravir providing a 50% reduction in the hospitalization rate and a 100% reduction in the death rate among patients within five days of symptomatic illness. “The impact on vaccine manufacturers such as Moderna should be limited,” ODDO wrote in a report to investors. “We believe that molnupiravir can be complementary to the COVID-19 vaccine but not a competitor.”

FiercePharma - October 5, 2021

View the full story here: https://www.fiercepharma.com/pharma/merck-s-molnupiravir-will-be-complementary-but-not-a-competitor-to-covid-19-vaccines-analyst